Provided by Tiger Fintech (Singapore) Pte. Ltd.

OS Therapies

1.60
-0.0300-1.84%
Post-market: 1.600.00000.00%16:05 EDT
Volume:108.73K
Turnover:167.97K
Market Cap:35.09M
PE:-2.10
High:1.62
Open:1.59
Low:1.50
Close:1.63
Loading ...

OS Therapies Awarded OST-HER2 Clinical Trial Data Presentation at MIB Agents FACTOR Osteosarcoma Conference

Business Wire
·
13 Mar

OS Therapies schedules Scientific Advice Meeting for OST-HER2 in Q3

TIPRANKS
·
11 Mar

OS Therapies Schedules United Kingdom’s Medicines and Healthcare products Regulatory Agency's (MHRA) Scientific Advice Meeting in the Third Quarter of 2025 for Review of its OST-HER2 Immunotherapy Candidate for Osteosarcoma

Business Wire
·
11 Mar

Calidi Biotherapeutics and OS Therapies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ACCESS Newswire
·
28 Feb

Join OS Therapies’ Exclusive Live Investor Webinar and Q&A Session on February 27

Business Wire
·
27 Feb

OS Therapies Forms Drug Conjugates Unit, Reviews Options for Tunable ADC, Drug Conjugates Platforms

MT Newswires Live
·
24 Feb

OS Therapies Is Maintained at Buy by D. Boral Capital

Dow Jones
·
24 Feb

Os Therapies Forms Subsidiary Os Drug Conjugates and Initiates Review of Strategic Options for Its Tunable ADC & Drug Conjugates Platforms

THOMSON REUTERS
·
24 Feb

Os Therapies Inc - in Discussions to Form Joint Ventures With ADC Companies

THOMSON REUTERS
·
24 Feb

OS Therapies receives patent notice of allowance for OST-HER2

TIPRANKS
·
20 Feb

Sector Update: Health Care Stocks Decline Late Afternoon

MT Newswires Live
·
15 Feb

Small-Cap OS Therapies Inks Commercial Manufacture Agreements For Lead Cancer Drug For Rare Type Of Bone Cancer

Benzinga
·
15 Feb

BUZZ-OS Therapies rises after starting commercial production of cancer therapy

Reuters
·
14 Feb

OS Therapies Says It Signed Manufacturing Deal for Lead Candidate OST-HER2

MT Newswires Live
·
14 Feb

BRIEF-OS Therapies Initiates Commercial-Ready Manufacturing Of OST-HER2 To Support Anticipated Biologics Licensing Authorization (BLA) Filing

Reuters
·
14 Feb

Os Therapies Initiates Commercial-Ready Manufacturing of Ost-Her2 to Support Anticipated Biologics Licensing Authorization (Bla) Filing

THOMSON REUTERS
·
14 Feb